Vir Biotechnology (VIR) Debt Ratio (2019 - 2025)

Vir Biotechnology (VIR) reported Debt Ratio of 0.01 for Q1 2025, up 16.56% sequentially from 0.01 in Q4 2024.

Vir Biotechnology (VIR) Debt Ratio (2019 - 2025) Analysis & Trends

Vir Biotechnology (VIR) has 5 years of Debt Ratio data on file, last reported at 0.01 in Q1 2025.

For the quarter ending Q1 2025, Debt Ratio changed N/A year-over-year to 0.01; the trailing twelve-month figure through Mar 2025 stood at 0.01 (changed N/A YoY), and the FY2024 full-year result was 0.01, changed N/A from the prior year.
Debt Ratio rose to 0.01 in Q1 2025, from 0.01 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.06 in Q3 2021 to a low of 0.01 in Q4 2024.
A 3-year average of 0.03 and a median of 0.02 in 2021 frame the typical range for Debt Ratio.
Peak annual rise in Debt Ratio reached 254.33% in 2021, while the deepest fall reached 4.19% in 2021.
Tracing VIR's Debt Ratio over 3 years: stood at 0.06 in 2021, then sank by 79.72% to 0.01 in 2024, then increased by 16.56% to 0.01 in 2025.
Business Quant data shows VIR's Debt Ratio at 0.01 in Q1 2025, 0.01 in Q4 2024, and 0.06 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Vir Biotechnology	1.38 Bn	1.38 Bn	-	-

Download Data